A month ago, the European Commission made a similar announcement with the purchase of 200 million doses of Novavax vaccine subject to regulatory approval. [JUSTIN TALLIS / AFP] |
Japan placed an order on Tuesday, September 7, for 150 million doses of the Covid-19 vaccine manufactured by the American company Novavax, subject to regulatory approval of the product.
Based on a "subunit" technology, that is to say virus-free but with proteins supposed to trigger an immune response, the vaccine produced by the American biotech Novavax is 90% effective, even against variants of Covid- 19 .
In charge of the manufacture and distribution of the vaccine in Japan, the company Takeda, the Japanese leader in the pharmaceutical field, wishes to market this new product from the beginning of 2022.
A month ago, the European Commission made a similar announcement with the purchase of 200 million doses of Novavax vaccine subject to regulatory approval.
48% OF THE JAPANESE POPULATION IS VACCINATED
In order to fight against the resurgence of the coronavirus on its territory, with a particularly violent fifth wave this summer, Japan has been undergoing restrictive health measures since mid-July. A situation that seems far from improving since these measures must be extended until the end of September, according to local media.
Set up late in the country, the vaccination campaign has been accelerating in recent months, although only 48% of the Japanese population is fully vaccinated.
Prime Minister Yoshihide Suga has announced a target of 60% of people fully vaccinated by the end of September 2021.